Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 233

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 233
---
 with historical rates used in these financial statements are as follows:

|          |     |       Average 
 Exchange Rate |     |          |     |               |     |          |     |        As 
        of |     |          |
|          |     |         Three 
  Months Ended 
 September 30, |     |          |     |          Nine 
  Months Ended 
 September 30, |     |          |     | September 
       30, |     | December 
      31, |
| Currency |     |          2024 |     |     2023 |     |          2024 |     |     2023 |     |      2024 |     |     2023 |
| 1 AUD =  |     |      0.67 USD |     | 0.65 USD |     |      0.66 USD |     | 0.67 USD |     |  0.69 USD |     | 0.68 USD |

F-13 (r) Reclassifications Certain prior period interim amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated condensed results of operations and comprehensive (loss) income, shareholders’ equity (deficit), or cash flows. (s) Share-Based Payments On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan also referred to as (“2022 Plan”). The 2022 Plan and related share-based awards are discussed more fully in Note 10. The Company accounts for share-based payments in accordance with ASC Subtopic 718, Compensation - Stock Compensation(“ASC 718”). The Company measures compensation for all share-based payment awards granted to employees, directors, and nonemployees, based on the estimated fair value of the awards on the date of grant. For awards that vest based on continued service, the service-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For service vesting awards with compensation expense recognized on a straight-line basis, at no point in time does the cumulative grant date value of vested awards exceed the cumulative amount of compensation expense recognized. The grant date is determined based on the date when a mutual understanding of the key terms of the share-based awards is established. The Company accounts for forfeitures as they occur. The Company estimates the fair value of all stock option awards as of the grant date by applying the